Search results
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for...
FOX 4 Kansas City· 16 hours ago"New data from the RESOLVE trial's first and second cohorts showed good tolerability and extended...
City-backed developer blows financing deadline for Poppleton
The Baltimore Banner· 3 hours agoNearly two decades into an agreement with the city of Baltimore that was supposed to spur the...
Earnings call: Celcuity reports Q1 financials, advances in cancer trials By Investing.com
Investing.com· 6 days agoThe company reported a net loss of $21.6 million, which is a significant increase from the $11.9...
Returns On Capital At Johnson Controls International (NYSE:JCI) Have Stalled
Simply Wall St. via Yahoo Finance· 52 minutes ago1b ÷ (US$43b - US$14b) (Based on the trailing twelve months to March 2024). Therefore, Johnson...s...
Revised Lift Fan Aircraft Concept Emerges From Special Ops X-Plane Program
THE WARZONE via Yahoo News· 13 hours agoIn April, Aurora advanced to Phase 1B, which will involve a preliminary design review. Whether any...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoPhase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia ...
Aileron Therapeutics (NASDAQ:ALRN) Announces Earnings Results, Misses Estimates By $0.72 EPS
ETF DAILY NEWS· 6 hours agoAileron Therapeutics (NASDAQ:ALRN – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.14 ...
3 Monster Stocks in the Making You Can Buy Right Now
Motley Fool via Yahoo Finance· 4 days agoThe company plans to advance the oral drug into a phase 2 study in the second half of this year. In addition to these three programs, Viking is...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 9 hours agoJanuary this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety and efficacy results from Part 2 of our Phase& ...
Exclusive: Scale AI secures $1B funding at $14B valuation as its CEO predicts big revenue growth and...
Fortune via AOL· 1 day ago“It's a pivotal moment for the industry,” he said. “I think we are now entering a phase where...
